市場調查報告書
商品編碼
1390729
2023-2028 年按組件(3D 生物列印機、支架、生物材料)、應用(研究、臨床)、最終用戶(醫院、研究組織和學術機構、生物製藥公司)和地區分類的 3D 生物列印市場報告3D Bioprinting Market Report by Component (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2023-2028 |
2022年,全球3D生物列印市場規模達到10.32億美元。展望未來, IMARC Group預計到2028年市場規模將達到26.21億美元,2022-2028年複合年成長率(CAGR)為16.81%。不斷成長的老年人口、對研發 (R&D) 活動的日益關注以及市場干擾的減少是推動市場發展的一些關鍵因素。
老年人口增加促進市場成長
目前,老年人口的成長是推動 3D 生物列印市場的主要因素之一。老年人群更容易患慢性病,因此對器官移植的需求增加。此外,各種醫療技術的廣泛應用以及業內有能力的專家的存在正在支持市場的成長。
報告涵蓋了市場結構、主要參與者的市場佔有率、參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外,也提供了所有主要公司的詳細資料。市場結構適度分散,該行業存在許多區域和全球參與者。由於資本投資高、進入和退出障礙過高,3D生物列印產業的新進入者數量適中。此外,由於幾家製造商之間差異不大,因此行業內產品差異化程度適中。
什麼是 3D 生物列印?
3D(3D)生物列印是一種專為開發精確解剖組織而設計的積層製造方法。它包括各種沉積和組裝工藝,例如直接寫入和雷射寫入、微沖壓、光刻、立體光刻、電子印刷和噴墨沉積。它依賴於使用活細胞、生物材料和活性生物分子製造的基於細胞的生物墨水的分解,以創建組織和器官的 3D 結構。它沉積多層生物材料來建造許多複雜的身體結構,如骨骼、皮膚、軟骨、血管移植物、氣管夾板和心臟組織。因此,3D生物列印在全球的醫院、研究機構、學術機構和生物製藥公司已被廣泛應用。
COVID-19大流行的疫情為各行業帶來了嚴重問題,也為許多國家帶來了前所未有的挑戰。但在 COVID-19 大流行期間,3D 生物列印已成為醫療保健產業的重要技術。由於醫療產品無法取得或短缺,對 3D 生物列印器官的需求增加。除此之外,多家公司正在使用最先進的 3D 生物列印平台來製造 SARS-CoV-2 感染的人類氣道和肺部類器官模型。此外,這些模型也被用於研究 COVID-19 疾病進展和快速藥物篩選。由於全球 COVID-19 病例不斷增加,生物印表機的使用率增加。除此之外,由於生產過程的減少,疫情對3D生物列印市場造成了輕微的阻礙。由於病毒的廣泛傳播,在大流行的頭幾個月裡,各個主要製造商被迫暫時關閉或暫停其生產過程。
目前,消費者減少動物試驗的意識不斷增強,這是積極影響市場的主要因素之一。除此之外,老年族群更容易患各種慢性病,因此對 3D 生物列印的需求不斷成長,這提供了積極的市場前景。此外,各種技術進步,例如器官晶片的發展,正在推動市場的成長。除此之外,世界各地大眾對再生醫學、癌症治療和幹細胞解決方案日益成長的需求也促進了市場的成長。此外,醫療保健行業中 3D 生物列印的採用率不斷上升,因為這是一個受干擾較少的市場,正在支持市場的成長。此外,主要製造商正專注於研發(R&D)活動,以引入生物列印組織,以降低新創新的成本並加快尋找新藥的過程。
The global 3D bioprinting market size reached US$ 1,032 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,621 Million by 2028, exhibiting a growth rate (CAGR) of 16.81% during 2022-2028. The growing geriatric population, increasing focus on research and development (R&D) activities, and less disrupted market represent some of the key factors driving the market.
Rising Geriatric Population Augmenting Market Growth
The rising geriatric population currently represents one of the primary factors driving the 3D bioprinting market. There is an increase in the demand for organ transplantation among the geriatric population, as they are more prone to chronic diseases. Moreover, the wide availability of various medical technologies and the presence of competent specialists in the industry is supporting the growth of the market.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is moderately fragmented with the presence of numerous regional and global players in the industry. The volume of new entrants is moderate in the 3D bioprinting industry due to the high capital investments and excessive entry and exit barriers. Moreover, the product differentiation is moderate in the industry due to little differentiation between several manufacturers.
What is 3D Bioprinting?
Three-dimensional (3D) bioprinting refers to an additive manufacturing method designed for the development of precise anatomical tissues. It comprises various deposition and assembling processes, such as direct and laser writing, microstamping, photolithography, stereolithography, electro-printing, and inkjet deposition. It relies on the decomposition of cell-based bio-inks that are manufactured using living cells, biomaterials, and active biomolecules to create 3D structures of tissues and organs. It deposits multiple layers of biomaterials to build numerous complex bodily structures, such as bones, skin, cartilage, vascular grafts, tracheal splints, and heart tissues. As a result, 3D bioprinting is widely utilized in hospitals, research organizations, academic institutes, and biopharmaceutical companies across the globe.
The COVID-19 pandemic outbreak caused severe problems for various industries and imposed unprecedented challenges on numerous countries. But 3D bioprinting has emerged as a vital technology in the healthcare industry during the COVID-19 pandemic. There was an increased demand for 3D bioprinted organs due to the unavailability or shortage of medical products. In addition to this, various companies were using state-of-the-art 3D bioprinting platforms to fabricate SARS-CoV-2-infected human airway and lung organoid models. Moreover, these models were being used to study COVID-19 disease progression and for rapid drug screening. There was an increased utilization of bioprinters on account of the rising COVID-19 cases across the globe. Apart from this, the pandemic has slightly hampered the 3D bioprinting market due to the reduction in the production process. Various key manufacturers were forced to temporarily shut down or pause their production process for the first few months of the pandemic due to the widespread of the virus.
At present, the increasing awareness among consumers to minimize animal testing represents one of the major factors influencing the market positively. Besides this, the growing demand for 3D bioprinting among the geriatric population, as they are more prone to various chronic diseases, is offering a positive market outlook. In addition, various technological advancements, such as the development of organ-on-a-chip, is propelling the growth of the market. Apart from this, the increasing demand for regenerative medicines, cancer therapeutics, and stem cell solutions among the masses around the world is contributing to the growth of the market. Moreover, the rising adoption of 3D bioprinting in the healthcare industry, as it is a less disrupted market, is supporting the growth of the market. Furthermore, key manufacturers are focusing on research and development (R&D) activities to introduce bioprinted tissues to reduce the cost of new innovations and enhance the process of finding new drugs.
IMARC Group provides an analysis of the key trends in each sub-segment of the global 3D bioprinting market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, application and end user.
3D Bioprinters
Syringe/Extrusion Bioprinting
Inkjet Bioprinting
Magnetic Levitation Bioprinting
Laser-assisted Bioprinting
Others
Scaffolds
Biomaterials
Living Cells
Hydrogels
Extracellular Matrices
Others
The report has provided a detailed breakup and analysis of the 3D bioprinting market based on the component. This includes 3D bioprinters (syringe or extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others). According to the report, 3D bioprinters (syringe or extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment due to the increasing utilization of syringe or extrusion-based bioprinting technology in printing various biological compounds or devices. In addition to this, the rising awareness among individuals about the 3D bioprinters technology is bolstering the growth of the market.
Research
Drug Research
Regenerative Medicine
3D Cell Culture
Clinical
Skin
Bone and Cartilage
Blood Vessels
Others
A detailed breakup and analysis of the 3D bioprinting market based on the application has also been provided in the report. This includes research (drug research, regenerative medicine, and 3D cell culture) and clinical (skin, bone and cartilage, blood vessels, and others). According to the report, research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share, as 3D printing technology is widely utilized among researchers to study the effects of different diseases and their progression and possible treatments. Moreover, it reduces the need to use lab animals for medical tests and dangerous trials on humans.
Hospitals
Research Organization and Academic Institutes
Biopharmaceuticals Companies
A detailed breakup and analysis of the 3D bioprinting market based on the end user has also been provided in the report. This includes hospitals, research organization and academic institutes, and biopharmaceuticals companies. According to the report, biopharmaceuticals companies accounted for the largest market share due to the increasing number of target therapies. In addition, the rising collaborations and mergers among biopharmaceutical companies to develop 3D bioprinting is positively influencing the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting. Some of the factors driving the North America 3D bioprinting market included the growing prevalence of various chronic diseases, presence of key players, and increasing private and government investment. Moreover, the introduction of laser bio-printing method that can make live 3D printed bio-tissues to create artificial tissues is positively influencing the market.
3D Systems Inc.
Aspect Biosystems Ltd.
Cellink
Cyfuse Biomedical K.K.
EnvisionTEC GmbH (Desktop Metal Inc.)
GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
Materialise
Organovo Holdings Inc.
Poietis
RegenHU
Stratasys Ltd.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.